Connect to share and comment

Danish drug maker Novo Nordisk Q1 net profits up 28 per cent on strong sales of diabetic drugs

The Canadian PressMay 1, 2013 04:15
COPENHAGEN - Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit rose 28 per cent on strong sales of its diabetic drugs. The world's largest insulin maker said net profit in the first three months of 2013 was 5.9 million kroner ($1 million), up from 4.7 million kroner. Revenue for the period came in at 20 billion kroner ($3.5 billion), up 13 per cent.

Novo Nordisk posts better-than-expected earnings

Agence France-PresseMay 1, 2013 03:45
Danish pharmaceutical group Novo Nordisk, the world's biggest producer of insulin for diabetes sufferers, on Wednesday topped analyst profit expectations for its first quarter of 2013 From January to March, the group posted a net profit of 5.982 billion Danish kroner (802 million euros), as it enjoyed strong sales of its diabetic drug Victoza and "modern insulins." Analysts polled by Dow Jones Newswires predicted 5.85 billion kroner in net profit.

FDA panel advises calcitonin salmon not be used for osteoporosis

March 5, 2013 20:00
March 5 (Reuters) - A panel of advisers to the U.S. Food and Drug Administration recommended on Tuesday that the agency no longer support the marketing of calcitonin salmon as a treatment for osteoporosis in post-menopausal women. The panel voted 12-9 that the benefit of calcitonin salmon products in treating bone-thinning associated with osteoporosis is outweighed by a potential increase in the risk of cancer. Calcitonin salmon is a man-made version of the hormone calcitonin that is found in salmon.

FDA staff say calcitonin salmon cancer risk appears plausible

March 1, 2013 10:45
March 1 (Reuters) - Staff reviewers for the U.S. Food and Drug Administration said that a potential increased risk of cancer with drugs containing calcitonin salmon appears plausible. In briefing documents released on Friday, the reviewers said the risk raises concerns about the overall risk versus benefit of calcitonin products to treat osteoporosis in postmenopausal women.

Sanofi boosts Lantus insulin production in Ireland

February 13, 2013 11:48
PARIS, Feb 13 (Reuters) - French drugmaker Sanofi said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of its top-selling insulin, Lantus. The company, which has been reshuffling research and production sites in the United States and Europe after the patent loss of several key medicines, aims to start making Lantus at the site in 2016, Sanofi said in a statement.

Novo Nordisk shares plunge on insulin setback

February 11, 2013 14:15
The world's biggest insulin producer Novo Nordisk Monday had 10.7 billion euros ($14.4 billion) wiped off its market value after the company said US authorities had rejected its applications for two new insulin treatments. Shares in the Danish company plunged by up to 15 percent after the US Food and Drug Administration (FDA) said "approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information. The FDA requested more cardiovascular data, which Novo Nordisk said it was unlikely to be able to provide this year.

Novo Nordisk shares plunges on insulin setback

February 11, 2013 06:00
Shares in the world's biggest insulin producer Novo Nordisk plunged by up to 15 percent on Monday after the company said US drug authorities had rejected its applications for two new insulin treatments. The Danish company said it had received a letter from the US Food and Drug Administration (FDA) stating "that approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information. The FDA requested more cardiovascular data, which Novo Nordisk said it was unlikely to be able to provide this year.

URGENT ¥¥¥ Novo Nordisk share plunges on insulin setback

February 11, 2013 05:16
Shares in the world's biggest insulin producer Novo Nordisk plunged by 13 percent on Monday after the company said US drug authorities had rejected its applications for two new insulin treatments. The Danish company said it had received a letter from the US Food and Drug Administration stating "that approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information. po/nsb/hd

Denmark faces Nokia moment as Novo weighs in at $100 bln

February 1, 2013 04:30
* Novo Nordisk biggest firm by market cap in the Nordics * Shares up almost 40 pct in 2012 on strong global insulin demand * Stock exchange changing key index to cap weighting at 20 pct By Mia Shanley and Shida Chayesteh COPENHAGEN, Feb 1 (Reuters) - Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.
Syndicate content